Comments
Suven Life Sciences has been granted a patent each by Eurasia, Europe, Israel and Macau for a drug used in the treatment of neuro-degenerative diseases.
“The grant of one product patent from Eurasia, one product patent from Europe, one product patent from Israel and one product patent from Macau correspond to the New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases,” Suven Life said in a BSE filing.
The patents are valid till 2030, the company added.
Suven Life CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
With these new patents, Suven has 15 granted patents from Eurasia, 18 from Europe, 8 from Israel and 5 from Macau.
“These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” Suven said.
Suven Life Sciences shares were trading up by 1.08 per cent at Rs 253.60 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.